68 Results
Sort By:
Published on November 8, 2023
Researchers at the Centre for Genomic Regulation and Vall d’Hebron Institute of Oncology, both in Barcelona, Spain, indicate that simultaneously inhibiting two specific proteins could slow the growth of triple-negative breast cancer (TNBC). The study, which appears in the journal EMBO Molecular Medicine, could have siginficant implications for this hard…
Published on November 1, 2023
A team of researchers at Baylor College of Medicine—and collaborating institutions—have discovered in animal model testing that Zotatifin a drug targeting the elF4A protein suppressed tumor cell proliferation and remodeled the tumor immune microenvironment and could be a key to treating triple-negative breast cancer (TNBC). The findings, reported in The…
Published on October 4, 2023
A team of investigators at Vanderbilt-Ingram Cancer Center, reporting in Cancer Discovery, has discovered a druggable target on natural killer cells that could create a therapeutic response in patients with immunotherapy-resistant triple-negative breast cancer. While immunotherapy has shown promise across a range of cancers and tumor types, only about 15%…
Published on February 15, 2023
Moffit Cancer Center researchers have reported in Nature Medicine that use of an oncolytic virus treatment in combination with chemotherapy can boost response rates during neoadjuvant therapy for triple-negative breast cancer (TNBC). The modified oncolytic herpes simplex 1 virus—talimogene laherparepvec (T-VEC)—is already approved to treat advanced melanoma. It is injected…
Published on August 10, 2022
In triple-negative breast cancer (TNBC), tumors express molecular markers of the epithelial-mesenchymal transition (EMT)—during which cells acquire the ability to move and migrate. Now, a new study from researchers at the the Johns Hopkins Kimmel Cancer Center has revealed an important role played by EMT programs in TNBC metastasis. This…
Published on February 9, 2022
Inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing, a new study by researchers at Yale Cancer Center shows. The discovery could be an early step in finding new therapeutics for this type of cancer, a very difficult disease to treat. The findings are published this…
Published on August 3, 2021
A significant association between statins and survival rates of triple-negative breast cancer (TNBC) patients has been found by researchers from The University of Texas MD Anderson Cancer Center. Their study suggests that since statins are low in cost, easy to access, and produce minimal side effects, these drugs could have…
Published on November 23, 2020
Researchers at the University of Virginia Cancer Center have identified a gene that is responsible for the spread of triple-negative breast cancer (TNBC) to other parts of the body, and which can render the cancer resistant to chemotherapy. Sanchita Bhatnagar, PhD, and her team have also developed a nanoparticle-delivered antibody…
Published on August 24, 2020
In a new study of triple-negative breast cancer, scientists from the Princess Margaret Cancer Centre in Toronto and led by senior scientists Cheryl Arrowsmith, Ph.D., and Mathieu Lupien, Ph.D., reported they have found a promising approach with a protein biomarker that may potentially identify patients for more precise targeted therapy.…
Published on November 19, 2018
A drug previously approved for treating migraine and epilepsy has been found to slow the growth of triple negative breast cancer in mouse models. Researchers in the U.S., Taiwan, and China carried out screening studies to identify known pharmacologically active compounds that trigger degradation of N-Ras, a key protein that…
Published on February 15, 2024
Researchers at the Johns Hopkins Kimmel Cancer Center have unveiled a promising new treatment approach for advanced HER2-negative breast cancer, using a three-drug combination that significantly improved responses in patients suffering from the disease. The study, published in Nature Cancer, involved a combination of a histone deacetylase (HDAC) inhibitor, which…
Published on January 31, 2024
Investigators at the University of Illinois Chicago (UIC) have developed new data that show a commonly ordered breast cancer biomarker test to help clinicians decide whether breast cancer patients should receive chemotherapy may be making bad recommendations for some Black women who take the test. The test, The Oncotype 21-gene…
Published on January 17, 2024
Researchers from the University of North Carolina have discovered that disrupting the cell’s innate immune response to DNA damage could be a mechanism of cancer resistance. In their paper in Nature, a team proposes that the protein MRE11 could serve as a key in activating the cGAS-STING pathway, which is…
Published on December 6, 2023
Patients with node-positive breast cancer that becomes node-negative after neoadjuvant chemotherapy can omit regional nodal irradiation (RNI) without increasing their risk for recurrence, suggests data presented at the 2023 San Antonio Breast Cancer Symposium. The de-escalation of treatment could spare a large proportion of patients the side effects associated with…
Published on November 27, 2023
A groundbreaking study conducted at Northwestern Medicine suggests that an artificial intelligence (AI) tool could spare breast cancer patients unnecessary chemotherapy treatments by more accurately predicting patient outcomes. The research, published today in Nature Medicine, shows that the AI tool outperformed the analysis of disease by expert pathologists. While current…